Patients with aggressive multiple sclerosis (MS) are at increased risk of rapid accrual of disability and disease progression, so early detection is critical
The window of opportunity for treating patients with aggressive MS is narrow, thus, conventional treatment paradigms need to be reconsidered
Aggressive disease warrants aggressive treatment
Therapeutic agents vary extensively throughout the world in terms of their availability, licensing, usage experience and logistics of implementation
Diligent monitoring is crucial for the timely discovery of suboptimal response to therapy
Multiple sclerosis (MS) is a CNS disorder characterized by inflammation, demyelination and neurodegeneration, and is the most common cause of acquired nontraumatic neurological disability in young adults. The course of the disease varies between individuals: some patients accumulate minimal disability over their lives, whereas others experience a rapidly disabling disease course. This latter subset of patients, whose MS is marked by the rampant progression of disability over a short time period, is often referred to as having 'aggressive' MS. Treatment of patients with aggressive MS is challenging, and optimal strategies have yet to be defined. It is important to identify patients who are at risk of aggressive MS as early as possible and implement an effective treatment strategy. Early intervention might protect patients from irreversible damage and disability, and prevent the development of a secondary progressive course, which thus far lacks effective therapy.
Your institute does not have access to this article
Open Access articles citing this article.
Neurotherapeutics Open Access 22 September 2021
Journal of Neurology Open Access 25 June 2021
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
CNS Drugs Open Access 24 July 2020
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278–285 (1998).
Frischer, J. M. et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175–1189 (2009).
Weinshenker, B. G. et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112, 1419–1428 (1989).
Ebers, G. C. Prognostic factors for multiple sclerosis: the importance of natural history studies. J. Neurol. 252, 15–20 (2005).
Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46, 907–911 (1996).
Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014).
Gholipour, T., Healy, B., Baruch, N. F., Weiner, H. L. & Chitnis, T. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology 76, 1996–2001 (2011).
Menon, S. et al. Characterising aggressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 84, 1192–1198 (2013).
Saccardi, R. et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult. Scler. 18, 825–834 (2012).
Confavreux, C., Vukusic, S. & Adeleine, P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126, 770–782 (2003).
Scalfari, A. et al. The natural history of multiple sclerosis, a geographically based study. 10. Relapses and long-term disability. Brain 133, 1914–1929 (2010).
Fisniku, K. L. et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131, 808–817 (2008).
Freedman, M. S. Induction versus escalation of therapy for relapsing multiple sclerosis: the evidence. Neurol. Sci. 29 (Suppl. 2), S250–S252 (2008).
Havla, J. B. et al. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch. Neurol. 69, 262–264 (2012).
Hakiki, B. et al. Withdrawal of fingolimod treatment for relapsing remitting multiple sclerosis: report of six cases. Mult. Scler. 18, 1636–1639 (2012).
Killestein, J. et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann. Neurol. 68, 392–395 (2010).
O'Connor, P. W. et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76, 1858–1865 (2011).
Cohen, J. A. et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J. Neurol. 260, 2023–2032 (2013).
Hutchinson, M. et al. The efficacy of natalizumab in patients with relapsing remitting multiple sclerosis:subgroup analysis of AFFIRM and SENTINEL. J. Neurol. 256, 405–415 (2009).
Freedman, M. S., Kaplan, J. M. & Markovic-Plese, S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J. Clin. Cell. Immunol. 4, 1000152 (2013).
Coles, A. J. Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics 10, 29–33 (2013).
Coles, A. J. et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253, 98–108 (2006).
Comi, G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol. Sci. 29 (Suppl. 2), S253–S255 (2008).
Reickmann, P. Concepts of induction and escalation therapy in multiple sclerosis. J. Neurol. Sci. 277 (Suppl. 1), S42–S45 (2009).
Edan, G. & Le Page, E. Induction therapy for patients with multiple sclerosis: why? When? How? CNS Drugs 27, 403–409 (2013).
Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829–1839 (2012).
Cossburn, M. et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77, 573–579 (2011).
Coles, A. J. et al. Efficacy and safety of alemtuzumab in treatment-naive with relapsing–remitting multiple sclerosis: four-year follow-up of the CARE-MS I study. Mult. Scler. 20 (Suppl. 1), P090 (2014).
Hartung, H. et al. Efficacy and safety of alemtuzumab in patients with relapsing–remitting multiple sclerosis who relapsed on prior therapy: four-year follow-up of the CARE-MS II study. Mult. Scler. 20 (Suppl. 1), P043 (2014).
Liliemark, J. The clinical pharmacokinetics of cladribine. Clin. Pharmacokinet. 32, 120–131 (1997).
Romine, J. S., Sipe, J. C., Koziol, J. A., Zyroff, J. & Beutler, E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing–remitting multiple sclerosis. Proc. Assoc. Am. Physicians 111, 35–44 (1999).
Rice, G. P., Filippi, M. & Comi, G. Cladribine and progressive MS: a clinical and MRI outcomes of multicenter controlled trial. Cladribine MRI Study Group. Neurology 54, 1145–1155 (2000).
Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416–426 (2010).
Montalban, X. et al. Oral cladribine as add on to IFN-β therapy in patients with active multiple sclerosis: results from the phase II ONWARD study. Neurology 80 (1_MeetingAbstracts), P07.099 (2013).
Leist, T. P. et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 13, 257–267 (2014).
Awad, A. & Stuve, O. Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther. Adv. Neurol. Disord. 6, 50–61 (2009).
Hauser, S. L. et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308, 173–180 (1983).
[No authors listed] The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 337, 441–446 (1991).
Weinstock-Guttman, B. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. Neurologist 3, 178–185 (1997).
Hohol, M. J. et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult. Scler. 5, 403–409 (1999).
Khan, O. A. et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult. Scler. 7, 185–188 (2001).
Perini, P. & Gallo, P. Cyclophosphamide is effective in rapidly deteriorating secondary progressive multiple sclerosis. J. Neurol. 250, 834–838 (2003).
Gladstone, D. E. et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch. Neurol. 63, 1388–1393 (2006).
de Bittencourt, P. R. & Gomes-da-Silva, M. M. Multiple sclerosis: long-term remission after a high dose of cyclophosphamide. Acta Neurol. Scand. 111, 195–198 (2005).
Schwartzman, R. J. et al. High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci. Ther. 15, 118–127 (2009).
Gobbini, M. I., Smith, M. E., Richert, N. D., Frank, J. A. & McFarland, H. F. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing–remitting multiple sclerosis. J. Neuroimmunol. 99, 142–149 (1999).
Krishnan, C. et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch. Neurol. 65, 1044–1051 (2008).
Patti, F. et al. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J. Neurol. Sci. 223, 69–71 (2004).
Smith, D. R. et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult. Scler. 11, 573–582 (2005).
Lebrun, C. et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult. Scler. 14, 399–405 (2008).
Gbadamosi, J. et al. Effects of mitoxantrone on multiple scleoris patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur. Neurol. 49, 137–141 (2003).
Hartung, H. P. et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360, 2018–2025 (2002).
Edan, G. et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry 62, 112–118 (1997).
Martinelli Boneschi, F. et al. Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews, Issue 5. Art. No.: CD002127. http://dx.doi.org/10.1002/14651858.CD002127.pub3.
Le Page, E. et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J. Neurol. Neurosurg. Psychiatry 79, 52–56 (2008).
Edan, G. et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J. Neurol. Neurosurg. Psychiatry 82, 1344–1350 (2011).
Ramtahal, J., Jacob, A., Das, K. & Boggild, M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J. Neurol. 253, 1160–1164 (2006).
Vollmer, T. et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult. Scler. 14, 663–670 (2008).
Barun, B. & Bar-Or, A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 142, 31–37 (2012).
Kappos, L. et al. Ocrelizumab in relapsing–remitting multiple sclerosis: a phase II, randomised, placebo-controlled, multicenter trial. Lancet 387, 1179–1187 (2011).
Naismith, R. T. et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 74, 1860–1867 (2010).
Hauser, S. L. et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008).
Pfender, N., Saccardi, R. & Martin, R. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr. Treat. Options Neurol. 15, 270–280 (2013).
Mancardi, G. & Saccardi, R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 7, 626–636 (2008).
Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing–remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 8, 244–253 (2009).
Burt, R. et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing–remitting multiple sclerosis. JAMA 313, 275–284 (2015).
Nash, R. A. et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing–remitting multiple sclerosis (HALT-MS): a 3 year interim report. JAMA Neurol. 72, 159–169 (2015).
Mancardi, G. L. et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 84, 981–989 (2015).
Bevan, C. J. & Cree, B. A. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 71, 269–270 (2014).
Prosser, L. A., Kuntz, K. M., Bar-Or, A. & Weinstein, M. C. The relationship between risk attitude and treatment choice in patients with relapsing–remitting multiple sclerosis. Med. Decis. Making 22, 506–513 (2002).
Johnson, F. R. et al. Multiple sclerosis patients' benefit–risk preferences: serious adverse event risks versus treatment efficacy. J. Neurol. 256, 554–562 (2009).
Heesen, C. et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult. Scler. 16, 1507–1512 (2010).
Atkins, H. L. & Freedman, M. S. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics 10, 68–76 (2013).
Kantarci, O. et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 51, 765–772 (1998).
Tremlett, H., Paty, D. & Devonshire, V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 66, 172–177 (2006).
Confavreux, C., Aimard, G. & Devic, M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103, 281–300 (1980).
Held, U. et al. Predictors of relapse rate in MS clinical trials. Neurology 65, 1769–1773 (2005).
Cree, B. A. et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 14, 2039–2045 (2004).
Jeannin, S., Deschamps, R., Chausson, N. & Cabre, P. Response to interferon-beta treatment in Afro-Caribbeans with multiple sclerosis. Mult. Scler. Int. 2011, 950126 (2011).
Correale, J. et al. Management of relapsing–remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization. J. Neurol. Sci. 339, 196–206 (2014).
Amato, M. P., Ponziani, G., Bartolozzi, M. L. & Siracusa, G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J. Neurol. Sci. 168, 96–106 (1999).
Kraft, G. H., Freal, J. E., Coryell, J. K., Hanan, C. L. & Chitnis, N. Multiple sclerosis: early prognostic guidelines. Arch. Phys. Med. Rehabil. 62, 54–58 (1981).
Wolfson, C. & Confavreux, C. Improvements to a simple Markov model of the natural history of multiple sclerosis. I. Short-term prognosis. Neuroepidemiology 6, 101–115 (1987).
Bergamaschi, R., Berzuini, C., Romani, A. & Cosi, V. Predicting secondary progression in relapsing–remitting multiple sclerosis: a Bayesian analysis. J. Neurol. Sci. 189, 13–21 (2001).
Scott, T. F. & Schramke, C. J. Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later. J. Neurol. Sci. 292, 52–56 (2010).
Trojano, M. et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J. Neurol. Neurosurg. Psychiatry 58, 300–306 (1995).
Weinshenker, B. G., Issa, M. & Baskerville, J. Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study. Arch. Neurol. 53, 353–358 (1996).
Phadke, J. G. Clinical aspect of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 113, 1597–1628 (1990).
Citterio, A., Azan, G., Bergamaschi, R., Erbetta, A., Cosi, V. Multiple sclerosis: disability and mortality in a cohort of clinically diagnosed patients. Neuroepidemiology 8, 249–253 (1989).
Runmarker, B. & Andersen, O. Prognostic factors in a multiple sclerosis incidence cohort with twenty five years of follow-up. Brain 116, 117–134 (1993).
Langer-Gould, A. et al. Clinical and demographic predictors of long-term disability in patients with relapsing–remitting multiple sclerosis: a systematic review. Arch. Neurol. 63, 1686–1691 (2006).
Zarei, M., Chandran, S., Compston, A. J. & Hodges, J. Cognitive presentation of multiple sclerosis: evidence for a cortical variant. J. Neurol. Neurosurg. Psychiatry 74, 872–877 (2003).
Weinshenker, B. G. et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114, 1057–1067 (1991).
Rudick, R. A., Lee, J. C., Simon, J. & Fisher, E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann. Neuro. 60, 236–242 (2006).
Brex, P. A. et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346, 158–164 (2002).
Filippi, M. et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44, 635–641 (1994).
O'Riordan, J. I. et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121, 495–503 (1998).
Kappos, L. et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353, 964–969 (1999).
Tomassini, V. et al. Predictors of long-term clinical response to interferon beta in relapsing remitting multiple sclerosis. J. Neurol. 253, 283–293 (2006).
Kornek, B. & Lassmann, H. Neuropathology of multiple sclerosis-new concepts. Brain Res. Bull. 61, 321–326 (2003).
Lukas, C. et al. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 81, 1351–1356 (2010).
Sailer, M. et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 52, 599–606 (1999).
Prosperini, L., Gallo, V., Petsas, N., Borriello, G. & Pozzilic, C. One-year MRI scan predicts clinical response to interferon beta in relapsing remitting multiple sclerosis. Eur. J. Neurol. 16, 1202–1209 (2009).
Rio, J. et al. Relationship between MRI lesion activity and response to IFN-β in relapsing remitting multiple sclerosis patients. Mult. Scler. 14, 479–484 (2008).
Lemtrada annex I: summary of product characteristics. European Medicines Agency [online], (2013).
Cohen, J. A. et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380, 1819–1828 (2012).
Sipe, J. C. et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344, 9–13 (1994).
Rivera, V. M., Jeffery, D. R., Weinstock-Guttman, B., Bock, D. & Dangond, F. Results from the 5-year, phase IV RENEW (registry to evaluate novantrone effects in worsening multiple sclerosis) study. BMC Neurology 13, 80 (2013).
Cocco, E. et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult. Scler. 9, 1225–1233 (2008).
Marriott, J. J., Miyasaki, J. M., Gronseth, G. & O'Connor, P. W. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 74, 1463–1670 (2010).
Stillwell, T. J. et al. Cyclophosphamide-induced hemorrhagic cystitis in Ewing's sarcoma. J. Clin. Oncol. 6, 76–82 (1988).
Berkson, B. M., Lome, L. G. & Shapiro, I. Severe cystitis induced by cyclophosphamide. Role of surgical management. JAMA 225, 605–606 (1973).
De Ridder, D. et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J. Urol. 159, 1881–1884 (1998).
Kanter, I. C. et al. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia 49, 914–920 (2008).
Wetzels, J. F. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis. Neth. J. Med. 62, 347–352 (2004).
Chen, J. T. et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 66, 1935–1937 (2006).
Roccatagliata, L. et al. The long-term effect of AHSCT on MRI measures of MS evolution: a five year follow-up study. Mult. Scler. 13, 1068–1070 (2007).
C.A.R. has acted as a consultant or advisor for Biogen, EMD Serono, Genzyme and Teva. H.J.M. has acted as a consultant or advisor for Biogen and Novartis. M.S.F. has acted as a consultant, advisor or steering-committee member for Actelion, Bayer Healthcare, Biogen, EMD Serono, Genzyme, Novartis, Opexa, Sanofi and Teva. He is a member of Genzyme's speakers' bureau, and has served on a study adjudication committee for Chugai.
About this article
Cite this article
Rush, C., MacLean, H. & Freedman, M. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol 11, 379–389 (2015). https://doi.org/10.1038/nrneurol.2015.85
Journal of Neurology (2022)
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
Journal of Neurology (2022)
Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients
Journal of Neurology (2022)